Page last updated: 2024-11-05

hepes

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID23831
CHEMBL ID1232545
CHEBI ID42334
MeSH IDM0010239

Synonyms (103)

Synonym
CHEMBL1232545
hepes,4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
PRESTWICK_256
4-(2-hydroxyethyl)-1-piperazine ethanesulfonic acid
nsc 166663
4-(2-hydroxyethyl)piperazin-1-ylethanesulphonic acid
4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid
einecs 230-907-9
n-2-hydroxyethylpiperazine-n-ethane sulfonic acid
nsc166663
1-piperazineethanesulfonic acid, 4-(2-hydroxyethyl)-
n-2-hydroxyethylpiperazine-n'-ethanesulfonic acid
nsc-166663
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
n-2-hydroxyethylpiperazine n',2'-ethanesulfonic acid
hepes ,
7365-45-9
n-2-hydroxyethylpiperazine-n'-ethanesulfonate
hepes, bioxtra, ph 5.0-6.5 (1 m in h2o), >=99.5% (titration)
hepes, bioxtra, suitable for mouse embryo cell culture, >=99.5% (titration)
hepes, >=99.5% (titration)
hepes, bioperformance certified, >=99.5% (titration), cell culture tested
CHEBI:42334 ,
1DG9
1D1P
hepes, bioultra, for molecular biology, >=99.5% (t)
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid ,
H0396
2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid
AKOS001696205
A837886
STK033062
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid
n-(2-hydroxyethyl)piperazine-n'-(2-ethanesulfonic acid)
2-(4-(2-hydroxyethyl)piperazin-1-yl)ethanesulfonic acid
ec 230-907-9
unii-rww266ye9i
rww266ye9i ,
5-23-02-00379 (beilstein handbook reference)
FT-0629149
hepes [mi]
hydroxyethylpiperazine ethane sulfonic acid [ii]
hydroxyethylpiperazine ethane sulfonic acid
n-2-hydroxyethylpiperazine n'-2'-ethanesulphonic acid
hydroxyethylpiperazine ethane sulfonic acid [inci]
EPITOPE ID:190604
S6831
n-2-hydroxyethylpiperazine-n'-2-ethanesulfonic acid
2-[4-(2-hydroxyethyl)-1-piperazinyl] ethanesulfonic acid
2-[4-(2-hydroxyethyl)-1-piperazinyl]ethane sulfonic acid
hebes
n-2 hydroxyethylpiperazine-n-2-ethane-sulfonic acid
n-(2-hydroxyethyl)-piperazine-n'-ethanesulfonic acid
hepes buffered saline
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethane-1-sulfonic acid
2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid #
n-2-hydroxyethylpiperazine-n-2-ethanesulfonic acid
4-(2-hydroxyethyl)piperazine-1-(2-ethanesulfonic acid)
n-2-hydroxyethylpiperazino-n'-2-ethanesulfonic acid
4-(2-hydroxyerhyl)piperazine-1-erhanesulfonic acid
mfcd00006158
203805-87-2
(4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
DTXSID5040382
hepes-buffered saline, ph 6.5 (5x)
hepes-buffered saline, ph 7.0 (2x for transfection)
J-521424
hepes (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)
F0001-1858
hepes, dry powder
hepes, >=99.0% (t)
hepes, >=99.0%
CS-0015167
HY-D0857
hepes, biochemical grade
hepes, vetec(tm) reagent grade, 99.5%
hepes, anhydrous, free-flowing, redi-dri(tm), >=99.5%
hepes, pharmaceutical secondary standard; certified reference material
hepes, nist srm 2181
hepes, 99.5%
4-(2-hydroxyethyl)-1-piperazine ethanesulphonate
15(r)-hydroperoxy-epe
4-(2-hydroxyethyl)-1-piperazine ethanesulfonate
4-(2-hydroxyethyl)-1-piperazineethane sulphonate
4-(2-hydroxyethyl)-1-piperazineethane sulfonate
4-(2-hydroxyethyl)-1-piperazine ethanesulphonic acid
4-(2-hydroxyethyl)-1-piperazineethane sulphonic acid
2-(4-(2-hydroxyethyl)piperazin-1-yl)ethanesulfonicacid
FT-0767998
BCP06984
Q418359
F20297
BS-17486
2-(4-(2-hydroxyethyl)piperazin-1-yl)ethane-1-sulfonic acid
tvz 7;was 13;nsc 166663
AMY23345
4-(2-hydroxylethyl)piperazine-1-ethanesulfonic acid
4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, hepes, n-(2-hydroxyethyl)piperazine-n'-(2-ethanesulfonic acid)
hepes (d18)
EN300-100251
2-(4-(2-hydroxyethyl)piperazinyl)ethanesulfonic acid (hepes)
BP-31246
Z1335657480

Research Excerpts

Overview

HEPES is a well-known buffering reagent used in cell-culture medium.

ExcerptReferenceRelevance
"HEPES is a well-known buffering reagent used in cell-culture medium. "( HEPES inhibits the conversion of prion protein in cell culture.
Belondrade, M; Casanova, D; Delmouly, K; Lehmann, S; Milhavet, O, 2011
)
3.25

Effects

HEPES has been widely employed as an organic buffer agent in cell culture medium. A Hepes-based medium has been devised which allows rapid Pi exchange across the plasma membrane of the human erythrocyte.

ExcerptReferenceRelevance
"HEPES has been widely employed as an organic buffer agent in cell culture medium as well as uptake and transport experiments in vitro. "( Effect of HEPES buffer on the uptake and transport of P-glycoprotein substrates and large neutral amino acids.
Kwatra, D; Luo, S; Mitra, AK; Pal, D; Paturi, KD; Shah, SJ, 2010
)
2.21
"1. A Hepes-based medium has been devised which allows rapid Pi exchange across the plasma membrane of the human erythrocyte. "( Multiple metabolic pools of phosphoinositides and phosphatidate in human erythrocytes incubated in a medium that permits rapid transmembrane exchange of phosphate.
Guy, GR; Hawkins, PT; King, CE; Michell, RH; Stephens, LR, 1987
)
0.79

Actions

ExcerptReferenceRelevance
"The HEPES, which displays surface activity, may facilitate the binding of metals to the algae for an initial exposure period."( Influence of N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid pH buffer on the biological response of marine algae.
Leal, MF; Vasconcelos, MT, 2002
)
0.8

Treatment

Hepes treatment prevented water acidification, but resulted in elevated plasma ammonia levels and reduced ammonia excretion rates. MEP treated with HEPES or < 5.0 mM of the Ca2+ or Mg2+ salts remained soluble and bound tobramycin.

ExcerptReferenceRelevance
"Hepes treatment prevented water acidification, but resulted in elevated plasma ammonia levels and reduced ammonia excretion rates."( The effects of CO2 and external buffering on ammonia excretion and Rhesus glycoprotein mRNA expression in rainbow trout.
Nawata, CM; Wood, CM, 2008
)
1.07
"Treatment with HEPES induces a beneficial effect by reduction of infarct size in repeated coronary reperfusion."( Beneficial effect of HEPES buffer in repeated coronary reperfusion.
Hammerman, H; Hir, J; Moscovitz, M; Ramadan, R, 2000
)
0.98
"MEP treated with HEPES or < 5.0 mM of the Ca2+ or Mg2+ salts remained soluble and bound tobramycin in an equilibrium dialysis bioassay."( Disparate efficacy of tobramycin on Ca(2+)-, Mg(2+)-, and HEPES-treated Pseudomonas aeruginosa biofilms.
Costerton, JW; Hoyle, BD; Wong, CK, 1992
)
0.86

Toxicity

ExcerptReferenceRelevance
" 7 These data show that five of the most commonly used artificial buffers, to study muscles in vitro, exert adverse effects on contractility of arterial and venous smooth muscle."( Adverse effects of artificial buffers on contractile responses of arterial and venous smooth muscle.
Altura, BM; Altura, BT; Carella, A; Turlapaty, PD, 1980
)
0.26
" These results demonstrate that the immediate toxic agent formed from SIN-1 decisively depends on the presence of Hepes."( The critical role of Hepes in SIN-1 cytotoxicity, peroxynitrite versus hydrogen peroxide.
de Groot, H; Kirsch, M; Lomonosova, EE; Rauen, U, 1998
)
0.83

Bioavailability

ExcerptReferenceRelevance
" Eventual implications in the bioavailability of copper(II) are also discussed."( Electrochemical evidence of surfactant activity of the hepes pH buffer which may have implications on trace metal availability to cultures in vitro.
Azenha, MA; Lage, OM; Vasconcelos, MT, 1996
)
0.54
" The metal taken up appears to stimulate the liberation of exudates that subsequently control the bioavailability of the metals and therefore metal uptake."( Influence of N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid pH buffer on the biological response of marine algae.
Leal, MF; Vasconcelos, MT, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Concentration-corrected dose-response relationships were plotted from previously published data on the effects of Pb on voltage-activated calcium channels of rat dorsal root ganglion (DRG) cells and Aplysia neurons."( Solubility of lead as lead (II) chloride in HEPES-Ringer and artificial seawater (Ca-ASW) solutions.
Carpenter, DO; Matthews, MR; Parsons, PJ,
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organosulfonic acidAn organic derivative of sulfonic acid in which the sulfo group is linked directly to carbon.
HEPES
HEPES
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSINE PHOSPHATASESaccharomyces cerevisiae (brewer's yeast)Ki250.0000250.0000250.0000250.0000AID977610
Chain A, Tyrosine PhosphataseBos taurus (cattle)Ki1,800.00001,800.00001,800.00001,800.0000AID977610
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Biochemistry, Feb-29, Volume: 39, Issue:8
Crystal structures of a low-molecular weight protein tyrosine phosphatase from Saccharomyces cerevisiae and its complex with the substrate p-nitrophenyl phosphate.
AID1811Experimentally measured binding affinity data derived from PDB2000Biochemistry, Feb-29, Volume: 39, Issue:8
Crystal structures of a low-molecular weight protein tyrosine phosphatase from Saccharomyces cerevisiae and its complex with the substrate p-nitrophenyl phosphate.
AID1811Experimentally measured binding affinity data derived from PDB1997Biochemistry, Jan-07, Volume: 36, Issue:1
Crystal structure of bovine low molecular weight phosphotyrosyl phosphatase complexed with the transition state analog vanadate.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB1997Biochemistry, Jan-07, Volume: 36, Issue:1
Crystal structure of bovine low molecular weight phosphotyrosyl phosphatase complexed with the transition state analog vanadate.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (664)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990155 (23.34)18.7374
1990's178 (26.81)18.2507
2000's184 (27.71)29.6817
2010's106 (15.96)24.3611
2020's41 (6.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 69.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index69.94 (24.57)
Research Supply Index6.57 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index128.49 (26.88)
Search Engine Supply Index2.09 (0.95)

This Compound (69.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (1.56%)5.53%
Reviews3 (0.43%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other690 (98.01%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]